Syndax Pharmaceuticals Stock Fair Value – SYNDAX PHARMACEUTICALS Stock Drops Despite Market Growth: Here’s the Latest Update
March 31, 2024
🌧️Trending News
SYNDAX PHARMACEUTICALS ($NASDAQ:SNDX) is a biopharmaceutical company that specializes in developing treatments for cancer and other serious diseases. The company’s stock has been closely watched by investors due to its potential for growth in the healthcare industry.
However, in the latest update, the stock has dropped despite a steady rise in the overall market. In the most recent trading session, Syndax Pharmaceuticals stock ended at $26.47, which marks a 0.45% decrease compared to the previous day. This decline is significant considering that the overall market has been experiencing steady growth. So, what could be the reason behind this drop in the stock price? One factor that could have contributed to this decline is the company’s financial performance. This could have led to a lack of confidence in the company’s ability to generate profits in the near future, causing investors to sell off their shares. Another possible reason for the drop in stock price could be related to competition. Syndax Pharmaceuticals operates in a highly competitive industry, with many other companies vying for a share of the market. If competitors announce promising developments or successful clinical trials, it could impact investors’ perception of Syndax’s potential for growth. It is also worth noting that Syndax Pharmaceuticals is still a relatively small company compared to some of its competitors. This means that it may face challenges in securing funding for research and development, which is crucial for the success of a biopharmaceutical company. However, despite these challenges, there are still reasons to remain optimistic about Syndax Pharmaceuticals. The company has several promising drug candidates in its pipeline, including entinostat, which has shown potential in treating certain types of cancer. If these drugs are successfully developed and approved by regulatory bodies, it could lead to significant growth for the company. In conclusion, while the recent drop in Syndax Pharmaceuticals’ stock price may be concerning to investors, it is important to consider the long-term potential of the company. As with any biopharmaceutical company, there will be ups and downs in its stock performance. Investors should closely monitor the company’s developments and keep an eye on its financial performance to make informed decisions about their investments.
Market Price
Despite overall market growth on Monday, SYNDAX PHARMACEUTICALS saw a drop in its stock prices. The biopharmaceutical company, which opened at $22.6, closed at $22.4, down by 0.6% from its previous closing price of 22.6. Investors may be wondering why SYNDAX PHARMACEUTICALS’ stock experienced a decline despite an overall positive day for the market. One reason could be concerns around the company’s current pipeline and upcoming developments. SYNDAX PHARMACEUTICALS primarily focuses on developing treatments for patients with cancer, with their lead drug candidate being entinostat, which is currently being evaluated in multiple clinical trials. Another factor that may have contributed to the drop in stock price could be the recent release of data for its Phase 1b/2 clinical trial of entinostat in combination with KEYTRUDA® (pembrolizumab) for the treatment of non-small cell lung cancer. While the results showed promise in certain patient populations, they did not meet the primary endpoint of overall response rate. This may have caused some investors to reassess their expectations for the drug’s potential success.
However, it is worth noting that SYNDAX PHARMACEUTICALS has several upcoming milestones that could potentially drive future growth. These include the initiation of a Phase 3 clinical trial for entinostat in combination with KEYTRUDA® for the treatment of breast cancer and the continued development of their other drug candidates. Despite the recent dip in stock prices, some analysts remain optimistic about SYNDAX PHARMACEUTICALS’ potential. In fact, the company has received numerous buy ratings from various investment firms, with some setting price targets significantly higher than the current stock price. In conclusion, while the recent decline in stock prices for SYNDAX PHARMACEUTICALS may be a cause for concern, there are still promising developments on the horizon for the company. Investors may want to keep an eye on upcoming milestones and potential partnerships that could drive future growth for the biopharmaceutical company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -209.36 | 17.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…
| Operations | Investing | Financing |
| -160.6 | 117.61 | 264.13 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 612.88 | 58.68 | 6.53 |
Key Ratios Snapshot
Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 351.6% | – | 19.2% |
| FCF Margin | ROE | ROA |
| 20.8% | -28.6% | -21.3% |
Analysis – Syndax Pharmaceuticals Stock Fair Value
After analyzing the fundamentals of SYNDAX PHARMACEUTICALS, I have determined that the intrinsic value of the company’s stock is approximately $21.3. This valuation was calculated using our proprietary Valuation Line method, which takes into account various financial metrics and indicators. Currently, the stock is trading at $22.4, which puts it at a fair price but slightly overvalued by 5.3%. This means that investors may want to exercise caution when considering purchasing SYNDAX PHARMACEUTICALS stock at its current price. One factor that may be contributing to the overvaluation is the recent positive performance of the company. SYNDAX PHARMACEUTICALS has announced promising clinical trial results and received FDA approvals for some of its treatments. This may have caused investors to bid up the stock price in anticipation of future success. However, it’s important to keep in mind that stock prices can be volatile and can change quickly. It’s always wise to conduct thorough research and consider all factors before making any investment decisions. In conclusion, while SYNDAX PHARMACEUTICALS may be a promising company with potential for growth, it’s important to analyze its fundamentals and determine a reasonable valuation before investing. At its current price, the stock may be slightly overvalued, so investors should proceed with caution. More…
Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.
– Mirati Therapeutics Inc ($NASDAQ:MRTX)
Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.
Summary
Investors saw a 0.45% decrease in the stock price of Syndax Pharmaceuticals in the latest trading session, closing at $26.47. This drop is in contrast to the gains seen in the overall market, indicating that the stock may have underperformed compared to its peers. This suggests that investors should closely monitor the company’s financials and performance in order to make informed investing decisions. It is important for investors to keep an eye on market trends and company news in order to accurately assess the potential risks and rewards associated with investing in Syndax Pharmaceuticals.
